Meitheal introduces albumin-bound injectable version under license from Hong Kong King-Friend

Meitheal Pharmaceuticals has announced the launch of a generic formulation of protein-bound paclitaxel in the United States. The chemotherapy agent, used primarily for patients with metastatic breast cancer and pancreatic cancer, enters the US market under an exclusive commercial licensing agreement with Hong Kong King-Friend Industry Co., Meitheal’s parent company.

The generic version of paclitaxel protein-bound particles for injectable suspension (albumin-bound) is bioequivalent to Abraxane and is now available in 100mg/vial single-dose format. The drug is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas, and locally advanced or metastatic non-small cell lung cancer.

According to the American Cancer Society, over 168,000 people in the US are currently living with metastatic breast cancer. Survival rates remain low, with fewer than one in three patients surviving beyond five years post-diagnosis. The availability of affordable and consistent chemotherapy options is considered vital for supporting long-term patient care.

Tom Shea, CEO of Meitheal, said: “Many patients living with difficult-to-treat cancers are faced with the unfortunate reality that the complex, life-saving treatments they need are too expensive or unavailable. #

“We’re committed to closing this gap – we believe that today’s launch is critical to ensuring that cancer patients get the medicines they need.

“We’re excited to bring this to market in the US and provide patients and providers with a reliable supply of an effective cancer care treatment.”

The launch adds to Meitheal’s portfolio of injectable generics, which now includes 68 marketed products. The company reported 12 launches in 2024 and plans to bring 20 additional products to market in 2025 across its core therapeutic categories.

Paclitaxel protein-bound is a chemotherapy agent that stabilizes microtubules, interrupting cell division and triggering apoptosis in cancerous cells. The albumin-bound formulation allows for solvent-free delivery and is often used in patients unable to tolerate standard paclitaxel due to hypersensitivity reactions.

The licensing agreement with Hong Kong King-Friend allows Meitheal to manufacture and commercialize the formulation in the United States. The company positions this move as part of a broader strategy to enhance access to high-demand oncology treatments while maintaining cost sustainability.

As generic competition expands for complex injectables, stakeholders will be watching how the launch impacts pricing dynamics and availability in oncology clinics, particularly in rural or under-resourced areas.